February 27, 2017
Verona puts COPD candidate RPL544 in focus for 2017, NASDAQ in four months?
According to Verona Pharma’s CEO, Dr. Jan-Anders Karlsson, the highlights of 2016 were encouraging clinical data for RPL554, additional financing from “a very experienced syndicate” of investors, and further strengthening of the company’s Board and executive team.